Status:
UNKNOWN
Evaluation of MMR Status and PD-L1 Expression Using Specimens Obtained by EUS-FNB in Patients With Pancreatic Cancer
Lead Sponsor:
Ponderas Academic Hospital
Collaborating Sponsors:
University of Medicine and Pharmacy Craiova
Conditions:
Pancreatic Cancer
Eligibility:
All Genders
18-90 years
Brief Summary
Pancreatic ductal adenocarcinoma (PDAC) has a suboptimal response to standard therapies that modestly impact survival due to its ability to evade host immune surveillance. Emerging evidence has shown ...
Eligibility Criteria
Inclusion
- Inclusion Criteria
- Age 18 to 90 years old
- men or women
- signed informed consent for EUS and EUS -FNB
- the diagnosis of adenocarcinoma histologically confirmed by FNB
- resectable, Unresectable, locally advanced and/or metastatic disease
- Exclusion Criteria:
- previous chemotherapy or radiotherapy
Exclusion
Key Trial Info
Start Date :
February 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 1 2022
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT03820921
Start Date
February 1 2019
End Date
January 1 2022
Last Update
January 29 2019
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.